Latest Healthcare in India Stories

ST. LOUIS, April 13 /PRNewswire-FirstCall/ -- K-V Pharmaceutical Company (NYSE: KVa/KVb) (the "Company") today announced it has appointed Stephen A. Stamp as Chief Financial Officer and Treasurer, effective April 7, 2010. Mr. Stamp will report directly to David Van Vliet, interim CEO of the Company. David Van Vliet, interim CEO of the Company stated, "Stephen brings decades of financial experience and deep healthcare industry knowledge to K-V and we are excited to welcome him aboard. We...

SAN FRANCISCO, April 6, 2010 /PRNewswire/ -- Germany is ranked number one in exporting research-intensive goods. This level of innovation drives the world's second largest market for biotechnology after the United States. Germany Trade & Invest will have representatives at this year's BayBio 2010 conference on April 7 in San Francisco, California, to highlight opportunities for American companies in Germany. There are more companies operating in the biotech and biomedical...

CALGARY, April 6 /PRNewswire-FirstCall/ - Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), is scheduled to present a corporate overview of the Company at BioFinance 2010 on Wednesday, April 7, 2010 at 10:30 a.m. (ET). The conference will be held at the Toronto Marriott Eaton Centre on April 6-8, 2010. About BioFinance 2010 BioFinance 2010 is the leading investor conference in Canada for the life sciences industry. This three-day event brings...

SAN FRANCISCO, April 1 /PRNewswire/ -- Biotech racked up impressive gains for both the month of March and the first quarter of 2010. The Burrill Biotech Select Index posted a 3.7 percent jump in value in March and an 8 percent overall gain for Q1 '10. The Dow also performed well in March, closing up 5.5 percent (4.5 percent for Q1 '10) with the NASDAQ doing even better - up 7 percent (5.7 percent for Q1 '10). "Biotechs certainly benefitted from the robust general markets this quarter,"...

CAMBRIDGE, Mass., March 30 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced that it has appointed Tamar D. Howson to its Board of Directors. Ms. Howson is currently a Partner at JSB-Partners, a transaction advisory firm serving the life sciences industry. Ms. Howson has extensive experience in licensing, collaborations and M&A...

LAKE FOREST, Ill., March 9 /PRNewswire/ -- Bioniche Pharma, a leading developer and manufacturer of injectable pharmaceuticals, announced today the launch of Mefoxin® (cefoxitin injection) frozen premix bags. The launch marks the company's first product offering to be supplied in a frozen premix bag presentation. Mefoxin (cefoxitin injection) is manufactured by Baxter Healthcare Corporation using Baxter's proprietary GALAXY container technology. (Logo:...

SAN DIEGO, March 8 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, today announced that it will release its fourth quarter and full year ended December 31, 2009 financial results after the market closes on Monday, March 15, 2010. Cadence management will host a conference call and live webcast to discuss the...

ROCKVILLE, Md., Feb. 5 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) a clinical-stage vaccine company, announced today that Dr. Rahul Singhvi, President and Chief Executive Officer of Novavax will be presenting at the 12th Annual BIO CEO & Investor Conference on February 8th, 2010 at 10:00 am local time. Hosted by the Biotechnology Industry Organization (BIO), the 12th Annual BIO CEO & Investor Conference will take place February 8-9 at the Waldorf=Astoria, New York. Dr....

ALEXANDRIA, Va., Feb. 4 /PRNewswire/ -- Oxford Finance Corporation today announced that it is the agent and primary lender for a $25 million credit facility provided to EUSA Pharma. MidCap Financial and Silicon Valley Bank are co-lenders in the transaction. EUSA Pharma is a specialty pharmaceutical company that focuses on oncology, pain control and critical care medicines which it markets predominately in Europe and the United States. The company currently has eight products on the market...

CALGARY, Feb. 4 /PRNewswire-FirstCall/ - Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will present a corporate overview of the Company at the 12th Annual BIO CEO & Investor Conference on Monday, February 8, 2010 at 3:00 p.m. ET. Hosted by the Biotechnology Industry Organization (BIO), the 12th Annual CEO & Investor Conference will take place February 8th and 9th at the Waldorf-Astoria Hotel in New York. A live audio link to the webcast...